Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Omeprazole enteric-coated capsules, developed by Hebei Sams Pharmaceutical, is a small molecule proton pump inhibitor (PPI) used for the treatment of gastric acid-related disorders. It works by irreversibly inhibiting the H+/K+-ATPase enzyme system, also known as the proton pump, in the gastric parietal cells, thereby suppressing the final step of gastric acid secretion. This specific formulation is an oral enteric-coated capsule designed to protect the acid-labile omeprazole from degradation in the stomach, ensuring release and absorption in the small intestine. It is indicated for conditions such as gastroesophageal reflux disease (GERD), peptic ulcer disease, erosive esophagitis, Zollinger-Ellison syndrome, and as part of a regimen for Helicobacter pylori eradication.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on omeprazole (Hebei Sams Pharmaceutical).